Business Context and Reporting Period
Processa Pharmaceuticals, Inc. (PCSA), an emerging growth company, filed this Form 8-K on June 1, 2020, to report a material definitive agreement entered into on May 24, 2020.
Key Financial Metrics
The filing does not provide current revenue, profit, cash flow, margin, debt, or liquidity figures. The document focuses exclusively on the terms of a new licensing agreement.
Material Changes
The primary material change is the entry into a License Agreement with Aposense, LTD. for the development and commercialization of ATT-11T, a next-generation irinotecan cancer drug. This agreement is structured as a Condition Precedent Agreement.
Outlook, Risks, and Unusual Items
- Agreement Terms: Upon satisfaction of conditions, Processa will receive an exclusive, royalty-bearing license with the right to sublicense.
- Financial Obligations: Aposense is eligible to receive up to $128 million in potential development and sales milestones.
- Royalties: Processa must pay royalties of 7% based on net sales.
- Contingencies: The grant of rights is subject to the satisfaction of specific conditions outlined in the agreement.
Investor Verification Checklist
- Verify the specific conditions precedent required to activate the exclusive license.
- Review the full text of the License Agreement (Exhibit 99.1) for detailed milestone definitions.
- Assess the company's current cash position to determine its ability to fund development and meet potential milestone payments.
- Confirm the regulatory status and development stage of the ATT-11T drug candidate.